A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback